84 related articles for article (PubMed ID: 2985414)
1. Differences in molecular heterogeneity of glucagon-like immunoreactivity in plasma and liver metastases of a patient with alpha-cell tumor.
Kohnert KD; Kändler C; Woltanski KP; Ziegler M
Exp Clin Endocrinol; 1985 Feb; 85(1):89-94. PubMed ID: 2985414
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic somatostatinoma: abundance of somatostatin-28(1-12)-like immunoreactivity in tumor and plasma.
Patel YC; Ganda OP; Benoit R
J Clin Endocrinol Metab; 1983 Nov; 57(5):1048-53. PubMed ID: 6137494
[TBL] [Abstract][Full Text] [Related]
3. Molecular forms of glucagon-like peptide-1 in human pancreas and glucagonomas.
Uttenthal LO; Ghiglione M; George SK; Bishop AE; Polak JM; Bloom SR
J Clin Endocrinol Metab; 1985 Sep; 61(3):472-9. PubMed ID: 2991321
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
[TBL] [Abstract][Full Text] [Related]
5. Secretory response and immunochemical heterogeneity of glucagon in plasma and tumor extracts of a patient with glucagonoma.
Torre L; Vazquez JA; Blázquez E
Horm Res; 1986; 23(3):159-66. PubMed ID: 3005153
[TBL] [Abstract][Full Text] [Related]
6. Plasma immunoreactive glucagon fractions in four cases of glucagonoma: increased "large glucagon-immunoreactivity".
Recant L; Perrino PV; Bhathena SJ; Danforth DN; Lavine RL
Diabetologia; 1976 Aug; 12(4):319-26. PubMed ID: 183997
[TBL] [Abstract][Full Text] [Related]
7. Secretion by glucagonomas of a possible glucagon precursor.
Weir GC; Horton ES; Aoki TT; Slovik D; Jaspan J; Rubenstein AH
J Clin Invest; 1977 Feb; 59(2):325-30. PubMed ID: 833279
[TBL] [Abstract][Full Text] [Related]
8. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours.
Holst JJ
Diabetologia; 1983 May; 24(5):359-65. PubMed ID: 6307793
[TBL] [Abstract][Full Text] [Related]
9. [Glucagonoma with diabetic ketoacidosis; case report].
Lefebvre J; Lelièvre G; Dalle-Furnari MA; Proye C; Mazzuca M; Garraud JC; Luyckx A; Linquette M
Diabete Metab; 1982 Sep; 8(3):191-5. PubMed ID: 6292011
[TBL] [Abstract][Full Text] [Related]
10. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma.
Valverde I; Lemon HM; Kessinger A; Unger RH
J Clin Endocrinol Metab; 1976 May; 42(5):804-8. PubMed ID: 178682
[TBL] [Abstract][Full Text] [Related]
11. Identification of glucagon in the gastrointestinal tract.
Sasaki H; Rubalcava B; Baetens D; Blazquez E; Srikant CB; Orci L; Unger RH
J Clin Invest; 1975 Jul; 56(1):135-45. PubMed ID: 237936
[TBL] [Abstract][Full Text] [Related]
12. [A human pancreatic glucagonoma, ultrastructural, immunocytochemical and radioimmunological investigations (author's transl)].
Voigt JJ; Hollande E; Pradayrol L; Vinel JP; Gorguet B
Ann Pathol; 1981; 1(4):287-97. PubMed ID: 6274365
[TBL] [Abstract][Full Text] [Related]
13. A high molecular weight form of somatostatin-28 (1-12)-like immunoreactive substance without somatostatin-14 immunoreactivity in the rat pancreas. Evidence that somatostatin-14 synthesis can occur independently of somatostatin-28.
Patel YC
J Clin Invest; 1983 Dec; 72(6):2137-43. PubMed ID: 6139388
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitory effects of somatostatin analog (SMS 201-995) on pancreatic hormones in patients with malignant islet-cell carcinoma].
Fukushima H; Ueno S; Sakakida M; Takahashi T; Shirotani T; Araki E; Kishikawa H; Yamaguchi K; Nakamura N; Uzawa H
Nihon Naibunpi Gakkai Zasshi; 1988 Aug; 64(8):666-76. PubMed ID: 2852126
[TBL] [Abstract][Full Text] [Related]
15. A case with glucagonoma syndrome--heterogeneity of glucagon and insulin.
Fukushima H; Yamaguchi K; Uzawa H
Endocrinol Jpn; 1981 Oct; 28(5):575-82. PubMed ID: 6284494
[TBL] [Abstract][Full Text] [Related]
16. Immunologic characterization of plasma glucagon components in a patient with malignant glucagonoma.
Tanaka K; Watabe T; Shimizu N; Horiuchi T; Nakamura K; Yoshida H
Metabolism; 1984 Aug; 33(8):728-33. PubMed ID: 6087085
[TBL] [Abstract][Full Text] [Related]
17. The role of the liver in glucagon metabolism.
Jaspan JB; Huen AH; Morley CG; Moossa AR; Rubenstein AH
J Clin Invest; 1977 Aug; 60(2):421-8. PubMed ID: 874100
[TBL] [Abstract][Full Text] [Related]
18. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract.
Ghatei MA; Uttenthal LO; Christofides ND; Bryant MG; Bloom SR
J Clin Endocrinol Metab; 1983 Sep; 57(3):488-95. PubMed ID: 6874888
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin-producing pancreatic somatostatinoma.
Galmiche JP; Chayvialle JA; Dubois PM; David L; Descos F; Paulin C; Ducastelle T; Colin R; Geffroy Y
Gastroenterology; 1980 Jun; 78(6):1577-83. PubMed ID: 6102950
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma proglucagon-like component with a glucagon-secreting tumor. Effect of streptozotocin.
Danforth DN; Triche T; Doppman JL; Beazley RM; Perrino PV; Recant L
N Engl J Med; 1976 Jul; 295(5):242-5. PubMed ID: 180408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
